Trial Condition(s):
Hypertension
COugh among hypertensive patients treated with telmisartan, who had to stop previoUs ACE-I treatment due to couGH in Poland (COUGH)
Bayer Identifier:
14881
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
In the light of ONTARGET and TRANSCEND studies results, it would be interesting to investigate the real-life telmisartan treatment tolerability. It is well known and accepted that the Real-life setting is much more adequate to reflect the antihypertensive and safety properties of the drug in comparison to the organized and scheduled setting of the clinical trial. Because there are not much data on the cough in relation to telmisartan, therefore it would we worth to observe the cough frequency and general treatment tolerance in patients treated with telmisartan, who had to stop their previous ACE-I treatment due to cough.
Inclusion Criteria
- hypertension - age > 18 - ACE-I related cough
Exclusion Criteria
- Current treatment with telmisartan - Cholestatic disorders and severe hepatic failure - Allergy to telmisartan - Pregnancy and lactation period
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Poland | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
COugh among hypertensive patients treated with telmisartan, who had to stop previoUs ACE-I treatment due to couGH
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Cough frequency among telmisartan treated patients, who had to stop their previous ACE-I treatment due to coughTimeframe: 4 months after initiation
Secondary Outcome
- General tolerability and safety of telmisartan treatment among patients, who had to stop their previous ACE-I treatment due to coughTimeframe: 4 months after initiation
Additional Information
Copyright © Bayer
Powered by
